SeaStar Medical to present SAVE registry data on SCD-PED outcomes in pediatric sepsis-associated AKI at ASN Kidney Week 2026
ICU•SeaStar Medical said it will present late-breaking SAVE Registry results on its QUELIMMUNE pediatric device at ASN Kidney Week 2026 on Oct. 22 in Denver. The data indicate improved outcomes versus a historical cohort of pediatric patients with sepsis-associated acute kidney injury requiring renal replacement therapy.
1. Registry results presentation
SeaStar Medical flagged new post-approval registry results for its QUELIMMUNE pediatric device. The late-breaking poster will compare SAVE Registry outcomes with a historical cohort of pediatric patients with sepsis-associated acute kidney injury requiring renal replacement therapy, and the company said the data indicate improved patient outcomes versus historical experience.
2. Presentation details
The presentation is scheduled for Oct. 22, 2026, at ASN Kidney Week in Denver. The brief described the results as supporting the product’s real-world performance in an ultra-rare, high-mortality setting.
